Regensburger, Martin http://orcid.org/0000-0002-2172-7386
Ip, Chi Wang http://orcid.org/0000-0003-0484-385X
Kohl, Zacharias http://orcid.org/0000-0002-4147-8866
Schrader, Christoph http://orcid.org/0000-0001-5323-8299
Urban, Peter P. http://orcid.org/0000-0002-4899-1937
Kassubek, Jan http://orcid.org/0000-0002-7106-9270
Jost, Wolfgang H. http://orcid.org/0000-0002-8574-3297
Funding for this research was provided by:
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Received: 26 February 2023
Accepted: 16 March 2023
First Online: 24 March 2023
Declarations
:
: M. Regensburger was a speaker for Orphalan and received travel compensation from Desitin. Chi Wang Ip is a consultant and/or speaker for the companies Ipsen and Merz. Zacharias Kohl was consultant and/or speaker for AbbVie, Bial, Desitin, UCB, Novartis. Christoph Schrader was speaker and consultant for Abbvie and received travel grants from Abbbie, Merz Deutschland, and Desitin. Peter Urban reports no competing interests. Jan Kassubek has received honoraria or consultation fees from AbbVie, Bial, Biogen, Desitin, Esteve, Licher MT, Medtronic, NeuroDerm, Novartis, STADA, UCB Pharma, and Zambon; in addition, he is Specialty Chief Editor for <i>Frontiers in Neurology</i> and Associate Editor (Neurology) for <i>Therapeutic Advances in Chronic Disease</i>. W. Jost is or was a consultant and/or speaker for the following companies: Abbvie, Bial, Desitin, Kyowa Kirin, Stada, UCB, Zambon.